Julio Cesar Valencia Manrique, Maria Medina, David Frank
{"title":"Loose Change: Pancreatitis from a Coin-Laden Windsock Diverticulum.","authors":"Julio Cesar Valencia Manrique, Maria Medina, David Frank","doi":"10.14309/ajg.0000000000004252","DOIUrl":"https://doi.org/10.14309/ajg.0000000000004252","url":null,"abstract":"","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maryam K Ibrahim, Wasuwit Wanchaitanawong, Isita Tripathi, Sama Anvari, Xin Xiong, Tianxi Cai, Ashwin N Ananthakrishnan
{"title":"Comparative Risk of Cancer with non-TNF Advanced Therapies Versus Anti-TNF Therapy in Inflammatory Bowel Disease.","authors":"Maryam K Ibrahim, Wasuwit Wanchaitanawong, Isita Tripathi, Sama Anvari, Xin Xiong, Tianxi Cai, Ashwin N Ananthakrishnan","doi":"10.14309/ajg.0000000000004251","DOIUrl":"https://doi.org/10.14309/ajg.0000000000004251","url":null,"abstract":"<p><strong>Background: </strong>Safety is important when selecting advanced therapies for inflammatory bowel disease (IBD). Safety data for anti-interleukin therapy (anti-IL) or vedolizumab come from trials with limited follow-up, and direct comparisons with anti-tumor necrosis factors (anti-TNFs) for incident cancer are lacking. We evaluated cancer incidence in patients with IBD treated with anti-IL therapy or vedolizumab versus anti-TNFs.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of adults with IBD and no prior cancer who initiated anti-IL therapy, vedolizumab or anti-TNFs. Our primary outcome was incident cancer from 90 days after therapy initiation through discontinuation. We calculated incidence rates and performed Cox proportional hazards models.</p><p><strong>Results: </strong>We identified 4,019 advanced therapy starts: 995 anti-IL, 692 vedolizumab, and 2,332 anti-TNF starts, with mean therapy duration of 1096 days. In multivariable analysis, there was a trend towards a lower hazard of all cancers among anti-IL users compared to anti-TNF users (HR 0.47; 95% CI 0.21-1.04), which was significant on sensitivity analyses. There was no difference in hazard of skin cancers (HR 1.56; 95% CI 0.39-6.15); however, the hazard of non-skin cancer was significantly lower among anti-IL users compared to anti-TNF users (HR 0.28; 95% CI 0.09-0.81). When comparing vedolizumab to anti-TNFs, there was no significant difference in the hazard of all cancer (HR 0.52, 95% CI 0.24-1.12) and non-skin cancer (HR 0.63, 95% CI 0.29-1.39).</p><p><strong>Conclusions: </strong>We found no evidence of an increased cancer risk with anti-IL therapy compared with anti-TNF therapy in patients with IBD. There was no difference in the cancer risk between vedolizumab and anti-TNF therapy.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Amanda Siegel, Terrance Rodrigues, Jacob M Schauer, Leila Kia, Stephen Chang, Kiran Nimmagadda, David Shapiro, Nidhi Singh, Ronak V Patel, Rajesh N Keswani
{"title":"A Prospective Tandem Colonoscopy Study to Determine Proximal Colon Polyp Miss Rate Among Gastroenterology Trainees.","authors":"Amanda Siegel, Terrance Rodrigues, Jacob M Schauer, Leila Kia, Stephen Chang, Kiran Nimmagadda, David Shapiro, Nidhi Singh, Ronak V Patel, Rajesh N Keswani","doi":"10.14309/ajg.0000000000004256","DOIUrl":"https://doi.org/10.14309/ajg.0000000000004256","url":null,"abstract":"<p><strong>Background: </strong>Existing colonoscopy quality metrics have limited utility for trainees. In particular, the adenoma detection rate may reflect trainer rather than trainee competence. Polyp miss rates may be more objective and feasible metrics of trainee colonoscopy quality. The aim of this study was to assess the proximal colon adenoma miss rate (AMR) and sessile serrated polyp miss rate (SMR) among gastroenterology trainees using a tandem colonoscopy study design.</p><p><strong>Methods: </strong>We prospectively recruited adult patients scheduled for screening or surveillance colonoscopy during endoscopy blocks with one of six high-quality trainers. Trainees performed the insertion with attending supervision. The trainee then performed independent withdrawal and inspection of the proximal colon (cecum to splenic flexure), identifying polyps without attending input. Subsequently, the attending performed a second complete inspection of the proximal colon; polyps that were identified on the second pass were considered missed polyps.</p><p><strong>Results: </strong>In total, 134 patients underwent colonoscopy by 13 gastroenterology trainees over a 17-month period. The overall proximal colon neoplastic (adenoma and serrated) polyp miss rate was 42.6%. Among these, they missed 38.1% of tubular adenomas and 58.9% of sessile serrated polyps in the proximal colon. Approximately 67% of the missed neoplastic polyps were ≤5mm. Trainee AMR and SMR decreased with increasing colonoscopy experience.</p><p><strong>Conclusions: </strong>Trainees miss over 40% of proximal colon neoplastic polyps, including the majority of right sided sessile serrated polyps. Measuring polyp miss rates using tandem colonoscopy is a novel and feasible approach to objectively assessing colonoscopy quality among gastroenterology trainees.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Efficacy and safety of dabigatran in cirrhosis with chronic portal vein thrombosis: A randomized, placebo-controlled double-blind trial (DAB-PVT).","authors":"Babu Lal Meena, Golamari Srinivasa Reddy, Ankit Kumar Bhardwaj, Ankur Jindal, Rajan Vijayaraghavan, Vinod Arora, Shalini Thapar, Amar Mukund, Guresh Kumar, Shiv Kumar Sarin","doi":"10.14309/ajg.0000000000004254","DOIUrl":"https://doi.org/10.14309/ajg.0000000000004254","url":null,"abstract":"<p><strong>Introduction: </strong>Direct oral anticoagulants (DOACs) are emerging options for portal vein thrombosis (PVT) in cirrhosis, though their safety and efficacy remain uncertain. We evaluated the efficacy and safety of dabigatran for PVT recanalization.</p><p><strong>Methods: </strong>Eighty-four patients with cirrhosis and PVT were prospectively randomized to receive dabigatran(n=42; 150 mg twice daily) or placebo(n=42) for 12 months. The primary endpoint was complete recanalization(CR) of the portal vein at 12 months. Secondary endpoints included safety, clinical outcomes, and changes in the liver disease severity scores and mortality.</p><p><strong>Results: </strong>Patients were predominantly male(71.4%), with a mean age of 48.5± 9.1 years and median Child-Turcotte-Pugh(CTP) score of 8(7-8). Medium-to-large varices were present in 60.7%, prior variceal bleeding in 45.2%, and ascites in 54.8%. At 12 months, complete recanalization occurred in 27/42(64.3%) in dabigatran group compared to 9/42(21.4%) in the placebo group(p<0.001). On multivariable Cox regression, dabigatran treatment was independently associated with complete recanalization (adjusted HR, 4.35; 95% CI, 2.03-9.36; P<0.001), along with a more favorable baseline ALBI score (adjusted HR, 2.02; 95% CI, 1.02-4.01; P=0.044). Variceal bleeding episodes were less frequent with dabigatran (3 vs. 12; p = 0.008). Compared with placebo, patients receiving dabigatran showed greater improvement in CTP scores (ΔCTP -0.57 ± 1.17 vs. 0.19 ± 1.17; P=0.004) and ALBI scores (ΔALBI -0.29 ± 0.82 vs. 0.06 ± 0.49; P=0.020). Longitudinal mixed-effects analysis demonstrated significantly different trajectories for CTP and ALBI scores, whereas MELD trajectories were comparable between groups.</p><p><strong>Conclusion: </strong>In patients with Child-Pugh A/B cirrhosis and chronic PVT, dabigatran significantly increased complete portal vein recanalization compared with placebo with fewer bleeding events. The observed differences in clinical events and liver disease severity scores could be considered exploratory requiring evaluation in larger comparative studies.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alberto Barchi, C Prakash Gyawali, John Pandolfino, Gwen M C Masclee, Niek Warringa, Edoardo Vespa, Edoardo V Savarino, Renato Salvador, Sabine Roman, Dustin A Carlson, Rena Yadlapati, Albert J Bredenoord
{"title":"The role of high-resolution manometry in the assessment of altered foregut anatomy: scoping review and interpretation recommendations.","authors":"Alberto Barchi, C Prakash Gyawali, John Pandolfino, Gwen M C Masclee, Niek Warringa, Edoardo Vespa, Edoardo V Savarino, Renato Salvador, Sabine Roman, Dustin A Carlson, Rena Yadlapati, Albert J Bredenoord","doi":"10.14309/ajg.0000000000004250","DOIUrl":"https://doi.org/10.14309/ajg.0000000000004250","url":null,"abstract":"<p><strong>Introduction: </strong>The Chicago Classification provides high-resolution manometry (HRM) criteria for the diagnosis of primary esophageal motility disorders but does not address HRM findings in patients with altered foregut anatomy or post-surgical states.</p><p><strong>Material and methods: </strong>We performed a scoping review of three databases to identify studies reporting HRM findings in altered foregut anatomy, including anti-reflux and bariatric surgery, treated achalasia, head and neck surgery, and rarer conditions such as esophageal diverticula and esophageal atresia. The aim was to synthesize available evidence and provide pragmatic recommendations for HRM interpretation in these conditions not addressed by the Chicago Classification.</p><p><strong>Results: </strong>We identified 168 articles addressing esophageal dysmotility associated with altered foregut anatomy or post-interventional states. Obesity, esophageal diverticula and esophageal strictures can all result in physiological changes in HRM metrics. HRM assesses motor function in hiatus hernia and identifies post-fundoplication outflow obstruction (PFOO) or junctional disruption. Bariatric procedures substantially alter esophagogastric junction anatomy, resulting in hypocontractile or obstructive manometric patterns. Unsuccessfully treated achalasia is defined by elevated IRP and obstruction on provocative maneuvers; the terms adequately treated achalasia (ATA) and treated achalasia with outflow obstruction (TAOO) have been proposed. Pseudo-achalasia is manometrically indistinguishable from primary achalasia. Other conditions including radiation therapy, head and neck surgery and treated esophageal atresia can result in heterogenous and often non-specific HRM findings.</p><p><strong>Conclusions: </strong>The Chicago Classification cannot be applied to motility patterns observed in patients with altered foregut anatomy or following foregut surgery. Instead, HRM interpretation in these settings should integrate anatomic information and focus on clinically actionable findings, particularly obstructive states.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
William D Chey, Anthony J Lembo, David P Rosenbaum
{"title":"Correction to Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1).","authors":"William D Chey, Anthony J Lembo, David P Rosenbaum","doi":"10.14309/ajg.0000000000004216","DOIUrl":"https://doi.org/10.14309/ajg.0000000000004216","url":null,"abstract":"","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149376773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Letter to the Editor.","authors":"Nihaal Karnik","doi":"10.14309/ajg.0000000000004233","DOIUrl":"https://doi.org/10.14309/ajg.0000000000004233","url":null,"abstract":"","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149376776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anastasios Koulaouzidis, Wojciech Marlicz, Ervin Toth
{"title":"Letter to the Editor.","authors":"Anastasios Koulaouzidis, Wojciech Marlicz, Ervin Toth","doi":"10.14309/ajg.0000000000004226","DOIUrl":"https://doi.org/10.14309/ajg.0000000000004226","url":null,"abstract":"","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149376775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}